Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis
- PMID: 17316146
- DOI: 10.1592/phco.27.3.343
Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis
Abstract
Study objective: To compare non-transferrin-bound iron and markers of oxidative stress after single intravenous doses of iron dextran, sodium ferric gluconate, and iron sucrose.
Design: Prospective, open-label, crossover study.
Setting: University-affiliated general clinical research center.
Patients: Twelve ambulatory patients undergoing hemodialysis.
Intervention: Patients received 100 mg of intravenous iron dextran, sodium ferric gluconate, and iron sucrose in random sequence, with a 2-week washout period between treatments.
Measurements and main results: Serum samples for transferrin saturation, non-transferrin-bound iron, and malondialdehyde (MDA; marker of lipid peroxidation) were obtained before (baseline) and 30, 60, 120, and 360 minutes and 2 weeks after each iron infusion. A serum sample for hemeoxygenase-1 (HO-1) RNA was obtained at baseline and 360 minutes after infusion. Non-transferrin-bound iron values were significantly higher 30 minutes after administration of sodium ferric gluconate and iron sucrose compared with iron dextran (mean +/- SEM 10.1 +/- 2.2, 3.8 +/- 0.8, and 0.23 +/-0.1 microM, respectively, p<0.001 for sodium ferric gluconate vs iron dextran, p = 0.002 for iron sucrose vs iron dextran). A significant positive correlation was noted between transferrin saturation and the presence of non-transferrin-bound iron for sodium ferric gluconate and iron sucrose (r2 = 0.37 and 0.45, respectively, p<0.001) but not for iron dextran (r2 = 0.09). After sodium ferric gluconate, significantly more samples showed increases in MDA levels from baseline compared with iron sucrose and iron dextran (p = 0.006); these increased levels were associated with the presence of non-transferrin-bound iron, baseline transferrin saturation above 30%, baseline transferrin levels below 180 mg/dl, and ferritin levels above 500 ng/ml (p<0.05). However, only a transferrin level below 180 mg/dl was independently associated (odds ratio 4.8, 95% confidence interval 1.2-15.3).
Conclusion: Iron sucrose and sodium ferric gluconate were associated with greater non-transferrin-bound iron appearance compared with iron dextran. However, only sodium ferric gluconate showed significant increases in lipid peroxidation. The relationship between non-transferrin-bound iron from intravenous iron and oxidative stress warrants further exploration.
Similar articles
-
Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.Biometals. 2011 Aug;24(4):603-13. doi: 10.1007/s10534-011-9409-6. Epub 2011 Jan 13. Biometals. 2011. PMID: 21229380 Clinical Trial.
-
A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.Ann Pharmacother. 2011 Feb;45(2):241-7. doi: 10.1345/aph.1P466. Ann Pharmacother. 2011. PMID: 21304025 Review.
-
Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.Am J Health Syst Pharm. 2009 Jun 15;66(12):1101-4. doi: 10.2146/ajhp080220. Am J Health Syst Pharm. 2009. PMID: 19498125
-
Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.Am J Kidney Dis. 1999 Mar;33(3):471-82. doi: 10.1016/s0272-6386(99)70184-8. Am J Kidney Dis. 1999. PMID: 10070911 Clinical Trial.
-
Acute injury with intravenous iron and concerns regarding long-term safety.Clin J Am Soc Nephrol. 2006 Sep;1 Suppl 1:S19-23. doi: 10.2215/CJN.01420406. Clin J Am Soc Nephrol. 2006. PMID: 17699372 Review.
Cited by
-
The Labile Side of Iron Supplementation in CKD.J Am Soc Nephrol. 2015 Nov;26(11):2612-9. doi: 10.1681/ASN.2015010052. Epub 2015 May 21. J Am Soc Nephrol. 2015. PMID: 25999405 Free PMC article. Review.
-
Serum Concentrations of F2-Isoprostanes and 4-Hydroxynonenal in Hemodialysis Patients in Relation to Inflammation and Renal Anemia.Biomark Insights. 2008 May 27;3:419-428. doi: 10.4137/bmi.s363. Biomark Insights. 2008. PMID: 19578522 Free PMC article.
-
Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?J Blood Med. 2012;3:77-85. doi: 10.2147/JBM.S29204. Epub 2012 Aug 29. J Blood Med. 2012. PMID: 22973119 Free PMC article.
-
Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity.Pediatr Nephrol. 2008 Feb;23(2):311-5. doi: 10.1007/s00467-007-0529-8. Epub 2007 Aug 1. Pediatr Nephrol. 2008. PMID: 17668247
-
Plasma non-transferrin-bound iron uptake by the small intestine leads to intestinal injury and intestinal flora dysbiosis in an iron overload mouse model and Caco-2 cells.Sci China Life Sci. 2023 Sep;66(9):2041-2055. doi: 10.1007/s11427-022-2347-0. Epub 2023 Jul 11. Sci China Life Sci. 2023. PMID: 37452897
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical